Navigation Links
Peptic ulcer bacterium alters the body's defense system

Helicobacter pylori survives in the body by manipulating important immune system cells. This is shown in a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery may lead to new treatments against the common peptic ulcer bacterium.

About half of the world's population carries Helicobacter pylori, mainly in the stomach. Most infected individuals never experience any symptoms, but around 10% get peptic ulcers and around 1% develop stomach cancer. 'Carriers were often infected as children and if not treated with antibiotics, the bacterium remains in the body for life. The immune system alone is unable to eliminate the bacterium, and now we understand better why', says biologist Bert Kindlund, the author of the thesis.

The study shows that a type of cells in the immune system called regulatory T cells down-regulate the body's defence against Helicobacter pylori and thereby enable the bacterium to develop a chronic infection. 'If we could control the regulatory T cells, we could strengthen the immune system and help the body eliminate the bacterium. This could be a new treatment strategy against Helicobacter pylori', Kindlund continues.

In addition, the bacterium makes the immune system increase the number of regulatory T cells in the lining of the stomach. This also occurs with stomach cancer. 'An important question is where the increased number of regulatory T cells in the stomach lining come from. Knowing the answer to this question could help us develop a treatment for stomach cancer. What we have found so far is that the regulatory T cells are actively recruited from the bloodstream into the tumour, and once there they start multiplying faster', says Kindlund.


Contact: Elin Lindstrm Claessen
University of Gothenburg

Page: 1

Related medicine news :

1. An ideal therapy for peptic ulcer disease
2. What is the most effective therapy for low-dose aspirin induced peptic ulcer?
4. New therapeutic targets in the treatment of ulcerative colitis
5. Narrow band imaging colonoscopy identifies flat dysplastic lesions in ulcerative colitis patients
6. Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives
7. Immunosyn Announces the Successful Completion of First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
8. Although Remicade and Humira Are Being Increasingly Prescribed for Crohns Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
9. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
10. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
11. Novel toxin receptor discovered for ulcer-causing stomach pathogen
Post Your Comments:
Breaking Medicine News(10 mins):
Breaking Medicine Technology: